OraSure Technologies, Inc. (NASDAQ:OSUR) has been upgraded to Outperform in a report by Raymond James Financial, Inc. today.
- Updated: February 12, 2017
Just yesterday OraSure Technologies, Inc. (NASDAQ:OSUR) traded 0.19% higher at $8.85. OraSure Technologies, Inc.’s 50-day moving average is $8.88 and its 200-day moving average is $8.21. The last closing price is up 27.96% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.06% over the same time period. 1,728,458 shares of OSUR traded hands, up from an average trading volume of 520,032
Raymond James Financial, Inc. has upgraded OraSure Technologies, Inc. (NASDAQ:OSUR) to Outperform in a report released on Thursday February 09, 2017.
Recent Performance Chart
OraSure Technologies, Inc. has 52 week low of $5.57 and a 52 week high of $11.41 with a PE ratio of 35.03 and has a market capitalization of $0.
In addition to Raymond James Financial, Inc. reporting its stock price target, a total of 5 brokers have issued a research note on the company. The average stock price target is $8.60 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
Brief Synopsis On OraSure Technologies, Inc. (NASDAQ:OSUR)
OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. Its diagnostic products include tests, such as OraQuick Rapid HIV Test, OraQuick In-Home HIV Test, OraQuick HIV Self-Test, OraQuick HCV Rapid Antibody Test, OraQuick Ebola Rapid Antigen Test, OraSure QuickFlu Rapid Flu A&B Test, OraSure Collection Device, Molecular Collection Systems, Cryosurgical Systems (Skin Lesion Removal Products), Immunoassay Tests and Reagents, Western blot HIV-1 Confirmatory Test and Q.E.D. Saliva Alcohol Test. Its products are sold in the United States and internationally to clinical laboratories and hospitals.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.